Add BrightSurf on Google Email

Boston Children's Hospital


Open-label placebo offers new treatment for disorders of gut-brain interaction in children

Researchers at Boston Children's Hospital have found that open-label placebo treatment significantly reduces pain scores in children with functional abdominal pain or irritable bowel syndrome. The study also showed no side effects, making it a promising non-pharmacologic therapy for these difficult-to-treat conditions.

SourceBoston Children's Hospital·JournalJAMA Pediatrics·TypeRandomized controlled/clinical trial·DateJan 31, 2022

Inadequate sleep is bad for preteens’ brains

A study from Boston Children's Hospital found that inadequate sleep can jeopardize brain organization in early adolescence, leading to deficits in cognitive processes such as attention, reward, and memory. The research identified racial disparities in the impact of sleep on brain networks, with non-white participants experiencing dispr...

SourceBoston Children's Hospital·JournalCerebral Cortex Communications·DateNov 22, 2021

In tightly controlled study, low-carb diet improves cardiometabolic risk profile

A new study published in the American Journal of Clinical Nutrition found that a low-carb diet with high saturated fat levels produced better cardiovascular and metabolic profiles than a low-fat diet. The low-carb diet improved blood lipid profiles, increased adiponectin, and reduced lipoprotein(a), a risk factor for heart disease.

SourceBoston Children's Hospital·JournalAmerican Journal of Clinical Nutrition·TypeRandomized controlled/clinical trial·DateSep 28, 2021

The choroid plexus: A conduit for prenatal inflammation?

Two new studies reveal that the choroid plexus, a miniature organ in the brain, is a hotbed of immune system activity. The choroid plexus regulates brain development by secreting instructive cues into the cerebrospinal fluid and provides a protective barrier. However, when this barrier is challenged, the choroid plexus can act as a con...

SourceBoston Children's Hospital·JournalDevelopmental Cell·DateOct 9, 2020

A targeted treatment for emphysema?

Researchers developed a small engineered peptide called PR1P, which protects VEGF from degradation and reduces apoptosis in both cell cultures and live mice. The study found significant increases in VEGF levels and reductions in lung damage in mouse models of emphysema.

SourceBoston Children's Hospital·JournalAmerican Journal of Respiratory Cell and Molecular Biology·DateAug 4, 2020